Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02893-y
Abstract: Thrombopoietin receptor agonists (TPO-RAs) are used for treatment of chronic immune thrombocytopenia (ITP). Several studies have shown that TPO-RAs induce remission and sustained response, despite long-term discontinuation of therapy. Furthermore, TPO-RAs are effective in patients… read more here.
Keywords: patients newly; newly diagnosed; treatment; remission ... See more keywords
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
Sign Up to like & getrecommendations! Published in 2019 at "Blood reviews"
DOI: 10.1016/j.blre.2019.100647
Abstract: Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10-30% of cases after treatment tapering… read more here.
Keywords: tapering discontinuation; treatment; discontinuation; thrombopoietin receptor ... See more keywords
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2098119
Abstract: ABSTRACT Introduction Multiple agents are available for the management of chronic immune thrombocytopenia (ITP), including thrombopoietin-receptor agonists (TPO-RAs), rituximab, and fostamatinib. Although TPO-RAs are often selected as treatments for chronic ITP, when choosing between the… read more here.
Keywords: chronic immune; immune thrombocytopenia; tpo ras; avatrombopag ... See more keywords
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2201428
Abstract: ABSTRACT Introduction Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment, frequently leading to reduced relative dose intensity, and is associated with reduced survival. Given the lack of FDA-approved therapies for CIT, thrombopoietin receptor… read more here.
Keywords: chemotherapy induced; tpo ras; thrombopoietin receptor; induced thrombocytopenia ... See more keywords
Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0267342
Abstract: Aims of the study Thrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. This observational study aimed to gain… read more here.
Keywords: time; tpo ras; tpo; receiving tpo ... See more keywords
Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme
Sign Up to like & getrecommendations! Published in 2023 at "Medicina"
DOI: 10.3390/medicina59040659
Abstract: Background and Objectives: TPO-RAs (romiplostim/eltrombopag/avatrombopag) have broadly demonstrated high efficacy rates (59–88%), durable responses (up to three years) and a satisfactory safety profile in clinical trials. The effect of TPO-RAs is classically considered to be… read more here.
Keywords: treatment srot; tpo ras; tpo; sustained remission ... See more keywords
Effect of Thrombopoietin Receptor Agonist on Pregnant Mice
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14030514
Abstract: Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity. In this study, we… read more here.
Keywords: mice; thrombopoietin receptor; tpo ras; pregnant mice ... See more keywords